← Back to Search

Other

BHV-7000 for Bipolar Disorder

Phase 2
Waitlist Available
Research Sponsored by Biohaven Therapeutics Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Key
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 52 weeks
Awards & highlights

Summary

"This trial aims to assess how safe and well-tolerated BHV-7000 is in individuals with bipolar I disorder over a long period of time."

Who is the study for?
This trial is for individuals who have bipolar I disorder and have completed the parent study BHV7000-204. Women of childbearing potential (WOCBP) must not be pregnant, breastfeeding, or lactating to participate.
What is being tested?
The focus of this study is on assessing the long-term safety and tolerability of a medication called BHV-7000 in people with bipolar I disorder.
What are the potential side effects?
While specific side effects are not listed here, participants will be monitored for any adverse reactions to BHV-7000 over an extended period to understand its long-term safety profile.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 52 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Clinically Significant Laboratory Abnormalities
Number of Participants With Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and AEs judged to be related to study medication

Trial Design

1Treatment groups
Experimental Treatment
Group I: BHV-7000Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Biohaven Therapeutics Ltd.Lead Sponsor
10 Previous Clinical Trials
3,952 Total Patients Enrolled
1 Trials studying Bipolar Disorder
256 Patients Enrolled for Bipolar Disorder
~133 spots leftby Mar 2026